Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. View the full analysis here.

Value stocks are generally companies that trade at a price lower than their fundamental value or what their performance suggests they should be worth. Typically, these are shares of a company with ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

This was the stock's second consecutive day of losses.

This was the stock's third consecutive day of losses.